Intellia Therapeutics said Monday it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage. The company’s stock plummeted more than 35% in morning trading. Liver damage has been a known risk for many CRISPR-based medicines in development, in part because they often involve trying to knock out or modify a gene …
Read More »Intellia pauses two late-stage CRISPR gene-editing trials due to safety concern
